Nuvalent's Total Assets for the quarter that ended in Dec. 2023 was $732.38 Mil.
During the past 12 months, Nuvalent's average Total Assets Growth Rate was 21.20% per year.
During the past 3 years, the average Total Assets Growth Rate was 241.30% per year.
During the past 5 years, Nuvalent's highest 3-Year average Total Assets Growth Rate was 241.30%. The lowest was 225.00%. And the median was 233.15%.
Total Assets is connected with ROA %. Nuvalent's annualizedROA % for the quarter that ended in Dec. 2023 was -26.47%. Total Assets is also linked to Revenue through Asset Turnover. Nuvalent's Asset Turnover for the quarter that ended in Dec. 2023 was 0.00.
Nuvalent Total Assets Historical Data
The historical data trend for Nuvalent's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Nuvalent's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note:
The Net Income data used here is four times the quarterly (Dec. 2023) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Nuvalent's Asset Turnover for the quarter that ended in Dec. 2023 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Nuvalent Total Assets Related Terms
Thank you for viewing the detailed overview of Nuvalent's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
NUVL has been successfully added to your 